“Given his extraordinary R&D as well as managerial experience, extensive network, along with his deep understanding of Galapagos’ strengths and potential, we are convinced that Paul is uniquely qualified to lead Galapagos,” Raj Parekh, chairman of Galapagos, said in a statement.
Belgian drugmaker Galapagos NV on Wednesday named previous Johnson & Johnson senior leader Paul Stoffels as its CEO, successful April 1. Stoffels was the chief scientific official of Johnson & Johnson starting around 2012 and spearheaded the advancement of its single-shot COVID-19 vaccine which won U.S. regulatory approval in February last year. He resigned from J&J toward the finish of 2021 and will supplant current Galapagos top boss and co-founder Onno van de Stolpe after the last option’s planned retirement. Stoffels also served on the Galapagos board of directors from its foundation in 1999 until 2002.
Suggestion For You:
Galapagos develops treatments for inflammatory diseases and kidney ailments.
It has a drug, filgotinib, which has been approved in the European Union and some other markets to treat rheumatoid arthritis. The company collaborated with Gilead Sciences on the drug’s development.
For Latest News Follow us on Google News
- Show all
- Trending News
- Popular By week